Clinically grounded, game-based and always available — MIRDC’s AI system is redefining how children learn to communicate.
Updated
January 8, 2026 6:32 PM
A child practicing with a speech therapist. PHOTO: FREEPIK
Speech and language delays are common, yet access to therapy remains limited. In Taiwan, only about 2,200 licensed speech-language pathologists serve hundreds of thousands of children who need support—especially those with autism spectrum disorders or significant communication challenges. As a result, many children miss crucial periods of language development simply because help isn’t available soon enough.
MIRDC’s new AI-powered interactive speech therapy system aims to close that gap. Instead of focusing solely on articulation, it targets a wider range of language skills that many children struggle with: oral expression, comprehension, sentence building and conversational ability. This makes it a more complete tool for childhood speech and language development.
The system combines game-based learning, AI-driven guidance and automated language assessment into one platform that can be used both in clinics and at home. This integrated design helps children practice more consistently, providing therapists and parents with clearer insight into their progress.
The interactive game modules are built around clinically validated therapy methods. Imitation exercises, picture cards, storybooks and conversational prompts are turned into structured game levels, each aligned with a specific developmental goal. This step-by-step approach helps children move from simple naming tasks to more complex comprehension and response skills, all within a sequenced curriculum.
A key differentiator is the system’s real-time AI speech interpretation. As the child talks, the AI analyzes the response and generates tailored therapeutic cues—such as imitation, modeling, expansion or extension—based on the conversation. These are the same strategies used by speech-language pathologists, but now children can access them continuously, supporting more effective at-home practice and reducing long gaps between sessions.
After each session, the system automatically conducts a data-driven language assessment using 20 objective indicators across semantics, syntax and pragmatics. This provides clinicians and families with measurable, easy-to-understand reports that show how the child is progressing and which skills need more attention—something many traditional tools do not offer.
By offering a personalized, scalable and clinically grounded solution, MIRDC’s AI therapy system helps address the ongoing shortage of speech-language services. It doesn’t replace therapists; instead, it extends their reach, allows for more consistent practice and helps families support their child’s communication at home.
As an added recognition of its impact, the system recently earned two R&D 100 Awards, including the Silver Award for Corporate Social Responsibility. But at its core, the project remains focused on a simple mission: making high-quality speech therapy accessible to every child who needs a voice.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.